Adial Pharmaceuticals ADIL Income Statement (2017-2026)

NASDAQ ADIL
$6.22 +0.32 (+5.34%)
At close: Aug 21, 2026 · 4:00 PM EDT
Income Statement Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Shares Outstanding (Entity) (Quarter)
0.03M0.03M0.03M0.04M0.04M0.04M0.04M0.05M0.05M0.05M0.07M0.12M0.17M0.26M0.19M0.27M0.42M0.95M0.67M1.51M
Operating items
Research & Development (Quarter)
0.08M1.69M2.33M0.60M0.68M0.70M0.53M0.37M0.43M0.21M0.26M0.45M1.01M2.50M0.75M0.73M2.00M0.43M
Selling, General & Administrative (Quarter)
2.08M2.37M2.10M2.46M2.56M1.86M2.07M1.90M1.05M1.15M1.52M1.39M1.27M3.85M1.52M1.15M3.91M1.57M
Restructuring Costs (Quarter)
0.07M0.09M0.04M0.34M0.11M0.40M0.02M
Other Operating Expenses (Quarter)
2.24M1.55M-0.07M-0.09M-0.04M-0.34M-0.11M-0.40M-0.91M-0.56M-0.37M1.27M0.94M
Operating Expenses (Quarter)
4.40M4.06M5.98M3.06M3.24M2.55M2.60M2.27M1.48M1.36M0.89M1.28M1.92M6.34M1.27M2.27M2.82M5.91M2.00M
Operating Income (Quarter)
-4.40M-4.06M-5.98M-3.06M-3.24M-2.55M-2.60M-2.27M-1.48M-1.36M-0.89M-1.28M-1.92M-6.34M-1.27M-2.27M-2.82M-5.91M-2.00M
EBIT (Quarter)
-4.40M-4.06M-5.98M-3.06M-3.24M-2.55M-2.60M-2.27M-1.48M-1.36M-0.89M-1.28M-1.92M-6.34M-1.27M-2.27M-2.82M-5.91M-2.00M
Non-operating items
Interest & Investment Income (Quarter)
0.00M0.00M0.00M0.01M0.00M0.05M0.03M0.02M0.01M0.01M0.02M0.05M0.12M0.04M0.02M0.11M0.05M
Other Non Operating Income (Quarter)
-0.07M-0.27M0.05M0.15M-0.02M0.07M0.33M-0.01M0.06M-42.00-1.00-43.000.17M-861.000.16M
Non Operating Income (Quarter)
-0.04M-0.25M0.06M0.15M0.01M0.00M0.05M0.03M-0.03M0.01M-4.63M-0.17M-4.78M0.04M-0.20M-0.07M-0.02M
Net income details
EBT (Quarter)
-4.44M-4.32M-5.92M-2.91M-3.24M-2.55M-2.55M-2.24M-1.51M-1.35M-1.90M-6.48M-2.46M-11.13M-1.44M-2.33M-2.80M-5.81M-1.95M
Profit After Tax (Quarter)
-4.44M-4.32M-5.83M-2.91M-3.85M-3.11M-0.93M-2.91M1.09M-1.38M-0.97M-6.48M-2.46M-11.13M-1.44M-2.34M-3.02M-5.98M-2.02M
Income from Continuing Operations (Quarter)
-4.44M-4.32M-5.92M-2.91M-3.24M-2.55M-2.55M-2.24M-1.51M-1.35M-1.90M-6.48M-2.46M-11.13M-1.44M-2.33M-2.80M-5.81M-1.95M
Income from Discontinued Operations (Quarter)
0.61M0.56M-2.60M0.04M4.52M
Consolidated Net Income (Quarter)
-4.44M-4.32M-5.92M-2.91M-0.61M-1.99M-2.55M-0.67M-0.06M-0.04M-0.02M-6.48M-2.46M-11.13M-1.44M-2.33M-2.80M-5.81M-1.95M
Income towards Parent Company (Quarter)
-4.44M-4.32M-5.92M-2.91M-0.61M-1.99M-2.55M-0.67M-0.06M-0.04M-0.02M-6.48M-2.46M-11.13M-1.44M-2.33M-2.80M-5.81M-1.95M
Net Income towards Common Stockholders (Quarter)
-4.44M-4.32M-5.92M-2.91M-0.61M-1.99M-2.55M-2.91M0.22M-0.04M-0.02M-6.48M-2.46M-11.13M-1.44M-2.33M-2.80M-5.81M-1.95M
Additional items
EPS (Basic) (Quarter)
-157.80-135.96-199.21-78.50-15.70-48.42-63.65-68.634.86-0.79-0.28-54.81-14.69-47.67-7.44-8.91-6.59-6.55-1.43
EPS (Diluted) (Quarter)
-157.80-135.96-199.21-78.50-15.70-48.42-63.65-68.634.86-0.79-0.28-54.81-14.69-47.67-7.44-8.91-6.59-6.55-1.43
Shares Outstanding (Quarter)
0.03M0.03M0.03M0.04M0.04M0.04M0.04M0.04M0.05M0.05M0.06M0.12M0.17M0.23M0.19M0.26M0.42M0.89M0.67M1.37M
Shares Outstanding (Diluted) (Quarter)
0.03M0.03M0.03M0.04M0.04M0.04M0.04M0.04M0.05M0.05M0.06M0.12M0.17M0.23M0.19M0.26M0.42M0.89M0.67M1.37M
EBITDA (Quarter)
-4.40M-4.06M-5.98M-3.06M-3.24M-2.55M-2.60M-2.27M-1.48M-1.36M-0.89M-1.28M-1.92M-6.34M-1.27M-2.27M-2.82M-5.91M-2.00M
Interest Expenses (Quarter)
1.53M6.37M0.02M0.71M0.00M129.000.15M0.01M0.05M0.08M0.00M0.01M0.05M0.17M0.10M